PL3840756T3 - Ulepszona synteza 1,4-diazaspiro[5.5]undekan-3-onu - Google Patents
Ulepszona synteza 1,4-diazaspiro[5.5]undekan-3-onuInfo
- Publication number
- PL3840756T3 PL3840756T3 PL19853098.2T PL19853098T PL3840756T3 PL 3840756 T3 PL3840756 T3 PL 3840756T3 PL 19853098 T PL19853098 T PL 19853098T PL 3840756 T3 PL3840756 T3 PL 3840756T3
- Authority
- PL
- Poland
- Prior art keywords
- undecan
- diazaspiro
- improved synthesis
- synthesis
- improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/18—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722675P | 2018-08-24 | 2018-08-24 | |
| PCT/US2019/048029 WO2020041770A1 (en) | 2018-08-24 | 2019-08-23 | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3840756T3 true PL3840756T3 (pl) | 2026-03-30 |
Family
ID=69591326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19853098.2T PL3840756T3 (pl) | 2018-08-24 | 2019-08-23 | Ulepszona synteza 1,4-diazaspiro[5.5]undekan-3-onu |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11708337B2 (pl) |
| EP (1) | EP3840756B1 (pl) |
| KR (1) | KR102962306B1 (pl) |
| CN (2) | CN120817904A (pl) |
| AU (1) | AU2019325685B2 (pl) |
| ES (1) | ES3056198T3 (pl) |
| HR (1) | HRP20251693T1 (pl) |
| PL (1) | PL3840756T3 (pl) |
| RS (1) | RS67557B1 (pl) |
| SG (1) | SG11202101807SA (pl) |
| WO (1) | WO2020041770A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL317919A (en) | 2016-12-05 | 2025-02-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー１ セラピューティクス， インコーポレイテッド | 癌の治療に対する併用療法 |
| KR102962306B1 (ko) * | 2018-08-24 | 2026-05-08 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
| JP7853532B2 (ja) | 2020-05-19 | 2026-04-30 | ファーマコスモス ホールディング エー／エス | 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物 |
| EP4164653A4 (en) | 2020-06-15 | 2024-06-19 | G1 Therapeutics, Inc. | MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN112094241B (zh) * | 2020-09-19 | 2023-04-18 | 浙江凯普化工有限公司 | 一种1,4-二氮杂螺[5,5]十一烷-3-酮的制备方法 |
| KR20220143393A (ko) | 2021-04-16 | 2022-10-25 | 주식회사 에이치엘클레무브 | 라이다 장치 및 이의 제어 방법 |
| EP4626866A1 (en) | 2022-11-28 | 2025-10-08 | Assia Chemical Industries Ltd. | Novel trilaciclib intermediates, method of preparation and use thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6506760B1 (en) | 2000-04-14 | 2003-01-14 | Corvas International, Inc. | Substituted hydrazinyl heteroaromatic inhibitors of thrombin |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| EP1539714B1 (en) | 2002-09-11 | 2008-08-13 | Merck & Co., Inc. | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| DE602004017474D1 (de) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| RU2006117368A (ru) | 2003-10-23 | 2007-12-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные триазаспиропипередина, предназначенные для применения в качестве ингибиторов glyt-1 при лечении неврологических и психоневрологических нарушений |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| CA2553938A1 (en) * | 2004-01-08 | 2005-07-28 | F. Hoffmann-La Roche Ag | Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2 |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| JP2008512460A (ja) | 2004-09-08 | 2008-04-24 | メルク エンド カムパニー インコーポレーテッド | 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬 |
| US8003792B2 (en) | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| JP5190271B2 (ja) | 2005-01-14 | 2013-04-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤としての５員の環付加複素環式ピリミジン |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| EP1954135B1 (en) | 2005-11-18 | 2012-10-10 | Merck Sharp & Dohme Corp. | Spirolactam aryl cgrp receptor antagonists |
| US7951795B2 (en) | 2006-12-08 | 2011-05-31 | Merck Sharp & Dohme Corp. | Constrained spirocyclic compounds as CGRP receptor antagonists |
| WO2008109464A1 (en) | 2007-03-02 | 2008-09-12 | University Of Massachusetts | Spirolactam targeting compounds and related compounds |
| US20110002855A1 (en) | 2007-06-25 | 2011-01-06 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| MX2010011591A (es) | 2008-04-22 | 2010-11-09 | Astrazeneca Ab | Pirimidin-5-carboxamidas sustituidas 281. |
| ES2622559T3 (es) | 2008-07-29 | 2017-07-06 | Nerviano Medical Sciences S.R.L. | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| WO2010039997A2 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| AU2009310352A1 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| EP3025724B1 (en) | 2009-05-13 | 2018-07-11 | The University of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| CN102372701A (zh) * | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用 |
| EP2616470B1 (en) * | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| KR102186969B1 (ko) | 2010-10-25 | 2020-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| US8829102B2 (en) | 2010-10-27 | 2014-09-09 | Cabot Corporation | High loading carbon black masterbatch for pressure pipe applications |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| CA2870019C (en) | 2012-04-26 | 2020-08-18 | Francis Xavier Tavares | Synthesis of lactams |
| US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
| JP6430483B2 (ja) | 2013-03-15 | 2018-11-28 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 化学療法の間の正常細胞の一時的な保護 |
| US20160287592A1 (en) | 2013-04-08 | 2016-10-06 | Pharmacyclics Llc | Ibrutinib combination therapy |
| US20150031674A1 (en) | 2013-07-26 | 2015-01-29 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| WO2015061407A1 (en) | 2013-10-24 | 2015-04-30 | Francis Xavier Tavares | Process for synthesis of lactams |
| US9481591B1 (en) | 2013-12-16 | 2016-11-01 | Barbara Blake | Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water |
| WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| CN105622638B (zh) | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
| AU2017290362B2 (en) * | 2016-07-01 | 2021-08-05 | Pharmacosmos Holding A/S | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| JP2020506903A (ja) * | 2017-01-23 | 2020-03-05 | ファイザー・インク | Ｍａｇｌ阻害薬としての複素環式スピロ化合物 |
| KR102962306B1 (ko) * | 2018-08-24 | 2026-05-08 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
| TW202302541A (zh) | 2021-03-17 | 2023-01-16 | 美商翰森生物有限責任公司 | 含氮雜環酮、其製備方法和醫藥用途 |
| CN117460717A (zh) * | 2021-03-17 | 2024-01-26 | 翰森生物有限责任公司 | 含氮杂环酮、其制备方法和医药用途 |
-
2019
- 2019-08-23 KR KR1020217008239A patent/KR102962306B1/ko active Active
- 2019-08-23 ES ES19853098T patent/ES3056198T3/es active Active
- 2019-08-23 CN CN202510844339.8A patent/CN120817904A/zh active Pending
- 2019-08-23 WO PCT/US2019/048029 patent/WO2020041770A1/en not_active Ceased
- 2019-08-23 HR HRP20251693TT patent/HRP20251693T1/hr unknown
- 2019-08-23 AU AU2019325685A patent/AU2019325685B2/en active Active
- 2019-08-23 SG SG11202101807SA patent/SG11202101807SA/en unknown
- 2019-08-23 RS RS20251239A patent/RS67557B1/sr unknown
- 2019-08-23 EP EP19853098.2A patent/EP3840756B1/en active Active
- 2019-08-23 PL PL19853098.2T patent/PL3840756T3/pl unknown
- 2019-08-23 CN CN201980067524.3A patent/CN112839657B/zh active Active
-
2021
- 2021-02-24 US US17/184,354 patent/US11708337B2/en active Active
-
2023
- 2023-07-24 US US18/225,537 patent/US12264135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210179567A1 (en) | 2021-06-17 |
| EP3840756A4 (en) | 2022-04-27 |
| EP3840756A1 (en) | 2021-06-30 |
| KR20210049847A (ko) | 2021-05-06 |
| AU2019325685B2 (en) | 2025-07-24 |
| CN112839657A (zh) | 2021-05-25 |
| EP3840756B1 (en) | 2025-11-05 |
| US20240199556A1 (en) | 2024-06-20 |
| RS67557B1 (sr) | 2026-01-30 |
| ES3056198T3 (en) | 2026-02-18 |
| US11708337B2 (en) | 2023-07-25 |
| CN120817904A (zh) | 2025-10-21 |
| SG11202101807SA (en) | 2021-03-30 |
| EP3840756C0 (en) | 2025-11-05 |
| WO2020041770A1 (en) | 2020-02-27 |
| KR102962306B1 (ko) | 2026-05-08 |
| AU2019325685A1 (en) | 2021-03-18 |
| US12264135B2 (en) | 2025-04-01 |
| CN112839657B (zh) | 2025-07-25 |
| HRP20251693T1 (hr) | 2026-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251693T1 (hr) | Poboljšana sinteza 1,4-diazaspiro[5.5]undekan-3-ona | |
| DK3762385T3 (da) | Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner | |
| EP3765522A4 (en) | ANTI-CLAUDIN 18.2 ANTIBODIES | |
| DK4015003T5 (da) | Forbedret antistof-oligonukleotid-konjugat | |
| IL290445A (en) | [1,2,4]triazolo[1,5-c]quinazolin-5-amines | |
| DK3752490T3 (da) | Herbicide 3-azaspiro[5.5]undecan-8,10-dionforbindelser | |
| EP3692072A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| DK3402782T3 (da) | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decanderivater | |
| EP3906261A4 (en) | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES | |
| EP3947466A4 (en) | ANTI-HLA-DQ2.5 ANTIBODIES | |
| IL282999A (en) | 1,3,4-oxadiazolone compound and pharmaceutical | |
| CL2020001659S1 (es) | Empaque. | |
| EP3764445A4 (en) | ELECTRODE CATALYST | |
| EP3911656A4 (en) | SYNTHESIS OF 14-METHYL-16-OXABICYCLO[ 10.3.1]HEXADEC-12-EN | |
| ES2686136B1 (es) | Procedimiento de sintesis de 9,10-bis (clorometil) antraceno | |
| EP3925957A4 (en) | 1,3-DIOXOLEAN DERIVATIVE | |
| CL2020000667S1 (es) | Sintetizador. | |
| UA45025S (uk) | 1. ополоник | |
| CL2019002573S1 (es) | Pintalabios. | |
| UA44990S (uk) | 1. термос | |
| UA45173S (uk) | 1.-3. сівалка | |
| CL2020000451S1 (es) | Cápsula. | |
| CL2019002372S1 (es) | Portalón. | |
| JP2021075226A5 (pl) |